6-K
Argenx SE (ARGX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2025
Commission File Number: 001-38097
ARGENX SE
(Translation of registrant’s name into English)
Laarderhoogtweg 251101 EB Amsterdam, the Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXPLANATORY NOTE
On May 28, 2025, argenx SE (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information contained in this Current Reporton Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the Company’s Registration Statementson Forms S-8 (File Nos. 333-225375, 333-258253, and 333-274721), and to be part thereof from the date on which this CurrentReport on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
| Exhibit | Description |
|---|---|
| 99.1 | Press Release May 28, 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ARGENX SE | ||
|---|---|---|
| Date: May 28, 2025 | By: | /s/ Hemamalini (Malini) Moorthy |
| Name: Hemamalini (Malini) Moorthy | ||
| Title: General Counsel |
Exhibit 99.1
argenx Announces Results of AnnualGeneral Meeting of Shareholders
May 28, 2025 – 10:01 PM CET
Amsterdam,the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held on May 27, 2025.
91.1% of the Company’s share capital was represented at the Annual General Meeting.
All items on the agenda received the required majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). This agenda item received a 73.0% majority where a 75% majority was required.
As part of the approved resolutions:
| · | The Company’s 2024 remuneration report received a 76.7% majority in favor<br>advisory vote; |
|---|---|
| · | The Company's annual report and annual accounts for the financial year ending December<br>31, 2024 were approved with a 99.9% majority; |
| --- | --- |
| · | Anthony Rosenberg has been re-appointed as non-executive director to the Board of<br>Directors for a term of two years with a 93.6% majority; and |
| --- | --- |
| · | The Board of Directors was authorized to issue shares and grant rights to subscribe<br>for shares in the share capital of the Company for up to 10% of the outstanding share capital at the date of the meeting and for a period<br>of 18 months from the meeting and to limit or exclude statutory pre-emptive rights with a 99.4% majority. |
| --- | --- |
The voting result and all documents relating to the shareholders’ meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Forfurther information, please contact:
Media:
Ben Petok
Bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com